Neutrophil extracellular traps

Volition appoints Dr Andrew Retter as Chief Medical Officer

Retrieved on: 
Tuesday, March 19, 2024
NHS foundation trust, Thrombosis, Sepsis, Guy, Disease, Neutrophil extracellular traps, Consultant, Patient, Research, Intensive care medicine, Respiratory failure, ECMO, NETS, Cancer, Heart, Nursing care plan, Clinical governance, Nursing

HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.

Key Points: 
  • HENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024.
  • Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs.
  • Cameron Reynolds, President and Group Chief Executive Officer at Volition, said: "We are delighted to welcome Andrew to Volition.
  • As Chief Medical Officer he will be vital to our success – ensuring the needs of the patient are placed at the heart of our research, development and commercialization activities."

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Cetuximab, Jefferies Group, Research, Chemistry, Nivolumab, Table, NETS, IRS, NK, Pancreatic cancer, Head, 5T4, DCR, Investigational New Drug, Escape Room, SCCHN, Interim, MD Anderson Cancer Center, Congress, Net, Three Months, International Financial Reporting Standards, CMC, Immune system, International, ESMO, Neutrophil extracellular traps, University, STAT3, AACR, CM24, Conference, Tumor microenvironment, MOA, IND, Insurance, Acquisition, ADS, Drug resistance, Food, Average cost, CEACAM1, PDAC, Administration, Patient, Pharmaceutical industry

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Retrieved on: 
Wednesday, February 21, 2024
Health, Other Science, Clinical Trials, Research, Pharmaceutical, Science, Inflammation, Chronic obstructive pulmonary disease, Safety, Hypoxia (medical), Biomarker, Pharmacokinetics, Patient, MPH, Disease, COPD, Neutrophil extracellular traps, Pharmaceutical industry

RLS-0071 is the Company’s lead dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation and is currently in development for the treatment for hypoxic ischemic encephalopathy, acute graft-versus-host disease, and other rare and acute inflammatory diseases.

Key Points: 
  • RLS-0071 is the Company’s lead dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation and is currently in development for the treatment for hypoxic ischemic encephalopathy, acute graft-versus-host disease, and other rare and acute inflammatory diseases.
  • The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial to evaluate safety, pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease.
  • Approximately 24 hospitalized patients will receive doses of either RLS-0071 or placebo in addition to standard of care treatment for up to five days.
  • Key secondary endpoints include biomarkers of inflammation, physiological response to RLS-0071 compared to placebo, as well as clinical progression and resolution.

Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody

Retrieved on: 
Tuesday, December 5, 2023
Cancer research, Ocean Biomedical, Immunotherapy, Neoplasm, University, IND, Breast cancer, Antibody, Research, PD-1, Glioblastoma, Apoptosis, Yale University, NETS, TKI, Cancer, CTLA4, Neutrophil extracellular traps, Colorectal cancer, Journal, PTEN, BioRxiv, Growth, McGill University, Publication, Immunity, Science, Pharmaceutical industry

PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The groundbreaking discoveries by a team led by Dr. William Muller at McGill University and in collaboration with Dr. Elias demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.

Key Points: 
  • Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.
  • This groundbreaking paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors.
  • Although these findings were defined in NSCLC, they have potential effectiveness in other EGFR-mutation driven cancers including Glioblastoma and Colon cancer.
  • Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically.

Purple Biotech Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 21, 2023
Drug resistance, ADS, Nine Months, Conference, AACR, Neoplasm, Tumor microenvironment, Table, MOA, Nivolumab, NET, Research, Biomarker, CMC, International, Cetuximab, Administration, NETS, Pancreatic cancer, CM24, Serum, Head, Patent, International Financial Reporting Standards, Neutrophil, Insurance, BMS, Average cost, PDAC, Neutrophil extracellular traps, CEACAM1, Net, Bristol Myers Squibb, OS, PFS, Escape Room, Acceleration, Neck, Pharmaceutical industry

REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.
  • Recently reported biomarker data demonstrates CM24’s mechanism of action for this important indication in dire need of a more effective drug that prolongs survival,” stated Purple Biotech CEO, Gil Efron.
  • The increase was mainly due to clinical trials expenses in our CM24 study offset by lower CMC costs in 2023.
  • A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

Selecta Biosciences Announces Merger with Cartesian Therapeutics

Retrieved on: 
Monday, November 13, 2023
Acquisition, DNA, Entrepreneurship, CVR College of Engineering, Patient, Autoimmune disease, SVB Securities, Lancet Neurology, Webcast, CVR, Food, PIPE, Toxicity, Covington & Burling, Transfection, RNA, GMP, Therapy, Risk, Myasthenia gravis, AAAD, Pharmacokinetics, Mergers and acquisitions, Orphan, Autoimmunity, The Lancet, LLP, Neutrophil extracellular traps, Fatigue, Lupus, Muscle weakness, Event, Vaccine, Mobile phone, Pharmaceutical industry, Management, Security (finance), Selecta, Cartesian, Quality

and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.

Key Points: 
  • and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.
  • In connection with the merger, Selecta announced a $60.25 million private financing led by Timothy A. Springer, Ph.D., member of the Selecta Board of Directors.
  • Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc.
  • Selecta and Cartesian will host a conference call today, Monday, November 13, 2023, at 9:00 am ET to discuss the merger.

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Retrieved on: 
Tuesday, October 24, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Patient, IND, Food, Biomarker, Hypoxia (medical), Investigational New Drug, MD, HIE, Rodels-Realta railway station, Doctor of Philosophy, Inflammation, Quality of life, System, Immune system, Risk, Genetically modified bacteria, Safety, Hospital, AE, Food and Drug Administration, Chronic obstructive pulmonary disease, Death, COPD, Neutrophil extracellular traps, Pharmaceutical industry

RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for AE-COPD, acute graft-versus-host disease (aGvHD), hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.

Key Points: 
  • RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for AE-COPD, acute graft-versus-host disease (aGvHD), hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.
  • “Patients with chronic obstructive pulmonary disease (COPD) face the persistent threat of hospitalization, mechanical ventilation and death from an acute exacerbation, an acute worsening of symptoms triggered by a viral or bacterial infection, or environmental irritant.
  • “This FDA clearance marks an important new milestone for ReAlta as we explore the potential of RLS-0071 across multiple therapeutic areas."
  • The Phase 2 clinical trial will be a randomized, double-blind, placebo-controlled trial in hospitalized patients with AE-COPD.

US Ambassador Adler visits Belgian Volition

Retrieved on: 
Wednesday, October 18, 2023
Nu, NYSE, CE, Growth, Texas A&M University, Cancer, NETS, Dog, Sepsis, Volition (company), Kingdom, Neutrophil extracellular traps, Nursing, Volition, Atlantic Ocean

HENDERSON, Nev., Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S.

Key Points: 
  • HENDERSON, Nev., Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S.
  • Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium.
  • Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis.
  • Gaetan Michel, Chief Operating Officer at Volition, said: "We were delighted to welcome Ambassador Adler to Volition today, to introduce our expert team, showcase our transformative epigenetic technology, and highlight its potential to improve patient outcomes worldwide.

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Retrieved on: 
Friday, October 6, 2023
Neoplasm, NETS, Survival, Tumor microenvironment, Drug resistance, CM24, AACR, CEACAM1, PDAC, Lymphocyte, Biomarker, American Association for Cancer Research, Neutrophil extracellular traps, Mall of America, Poster, Pancreatic cancer, Cancer, Nivolumab, NET, Escape Room, SOC, Conference, Serum, Neutrophil, Pharmaceutical industry, Medical imaging, Vaccine, Patient

The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.

Key Points: 
  • The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.
  • “These encouraging data, demonstrating increased survival of PDAC patients whose biopsies show higher CEACAM1-positive lymphocytes, are consistent with the CM24 Mechanism of Action (MoA) in suppressing the immune evasion and suggest CEACAM1 expressing lymphocytes as a potential biomarker for CM24 therapy” said Purple Biotech VP R&D, Dr. Hadas Reuveni.
  • “NETs and CEACAM1 will continue to be monitored and investigated in our ongoing randomized Phase 2 study of CM24 in pancreatic cancer patients,” stated Purple Biotech CEO, Gil Efron.
  • “We look forward to reporting data from this study in the near term.”

Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023

Retrieved on: 
Thursday, September 21, 2023
NETS, AACR, Neutrophil extracellular traps, Nivolumab, Pancreatic cancer, American Association for Cancer Research, Drug resistance, CM24, Survival, Escape Room, Neoplasm, Tumor microenvironment, Conference, Pharmaceutical industry, Patient

REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present a poster titled: “Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)” at the American Association for Cancer Research ( AACR ) Special Conference: Pancreatic Cancer, on September 28, 2023 at 4:40 pm ET in Boston.

Key Points: 
  • REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present a poster titled: “Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)” at the American Association for Cancer Research ( AACR ) Special Conference: Pancreatic Cancer, on September 28, 2023 at 4:40 pm ET in Boston.
  • New biomarker data presented at the AACR conference will be shared via a press release by Purple Biotech subsequent to the poster presentation.